Human Metabolism of Ornithine Phenylacetate: A Study in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ornithine phenylacetate (Primary)
- Indications Hepatic encephalopathy; Liver cirrhosis; Liver failure; Non-alcoholic fatty liver disease
- Focus Pharmacokinetics
- Acronyms OCERA OP
Most Recent Events
- 10 Apr 2019 Planned End Date changed from 1 Apr 2018 to 1 Apr 2021.
- 24 May 2017 New trial record